Antenatal and postnatal mental health: clinical management and service guidance : guidance (CG192)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
17 December 2014

Abstract

This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.

 MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby.  See update information for details. In March 2019, we produced a summary of NICE guidance to support the safe use of valproate. 

Recommendations

This guideline includes recommendations on:

Who is it for?

  • Healthcare professionals
  • Commissioners
  • Social services
  • Voluntary and private sectors
  • Women who have, or are at risk of, mental health disorders during pregnancy and the postnatal period and their partners, families and carers

Is this guideline up to date?

We checked this guideline in June 2017. We found no new evidence that affects the recommendations in this guideline. However, we have made some editorial or factual corrections.

Guideline development process

How we develop NICE guidelines

This guideline updates and replaces NICE guideline CG45 (February 2007) and section 1.5.6 of NICE guideline CG62 (March 2008).